Sheeja Sugunan1, S Bindusha2, S Geetha2, H R Niyas2, A Santhosh Kumar2. 1. Department of Pediatrics, SAT Hospital, Government Medical College, Thiruvananthapuram, Kerala. Correspondence to: Dr Sheeja Sugunan, Associate Professor, Department of Pediatrics, SAT hospital, Government Medical College Thiruvananthapuram, Kerala. sheejavimalk@gmail.com. 2. Department of Pediatrics, SAT Hospital, Government Medical College, Thiruvananthapuram, Kerala.
Abstract
OBJECTIVE: To study the clinical profile and outcome of children with MIS-C treated with methylprednisolone pulse therapy and /or intravenous immunoglobulin (IVIG). METHOD: This prospective observational study included children satisfying CDC MIS-C criteria admitted from September to November, 2020. Primary outcome was persistence of fever beyond 36 hours after start of immunomodulation therapy. Secondary outcomes included duration of ICU stay, mortality, need for repeat immunomodulation, time to normalization of CRP and persistence of coronary abnormalities at 2 weeks. RESULTS: Study population included 32 patients with MIS-C with median (IQR) age of 7.5 (5-9.5) years. The proportion of children with gastrointestinal symptoms was 27 (84%), cardiac was 29 (91%) and coronary artery dilatation was 11 (34%). Pulse methylprednisolone and intravenous immunoglobulin were used as first line therapy in 26 (81%), and 6 (19%) patients, respec-tively. Treatment failure was observed in 2/26 patients in methylprednisolone group and 2/6 patients in IVIG group. C-reactive protein levels less than 60mg/L by day 3 was seen in 17(74%) in methylprednisolone group and 2 (25%) in IVIG group (P=0.014). There was no mortality. At 2 weeks follow-up coronary artery dilatation persisted in 4 in methylprednisolone group and 1 in IVIG group. CONCLUSIONS: In patients with SARS-CoV-2 related MIS-C, methylprednisolone pulse therapy was associated with favorable short-term outcomes.
OBJECTIVE: To study the clinical profile and outcome of children with MIS-C treated with methylprednisolone pulse therapy and /or intravenous immunoglobulin (IVIG). METHOD: This prospective observational study included children satisfying CDC MIS-C criteria admitted from September to November, 2020. Primary outcome was persistence of fever beyond 36 hours after start of immunomodulation therapy. Secondary outcomes included duration of ICU stay, mortality, need for repeat immunomodulation, time to normalization of CRP and persistence of coronary abnormalities at 2 weeks. RESULTS: Study population included 32 patients with MIS-C with median (IQR) age of 7.5 (5-9.5) years. The proportion of children with gastrointestinal symptoms was 27 (84%), cardiac was 29 (91%) and coronary artery dilatation was 11 (34%). Pulse methylprednisolone and intravenous immunoglobulin were used as first line therapy in 26 (81%), and 6 (19%) patients, respec-tively. Treatment failure was observed in 2/26 patients in methylprednisolone group and 2/6 patients in IVIG group. C-reactive protein levels less than 60mg/L by day 3 was seen in 17(74%) in methylprednisolone group and 2 (25%) in IVIG group (P=0.014). There was no mortality. At 2 weeks follow-up coronary artery dilatation persisted in 4 in methylprednisolone group and 1 in IVIG group. CONCLUSIONS: In patients with SARS-CoV-2 related MIS-C, methylprednisolone pulse therapy was associated with favorable short-term outcomes.
Authors: Brian W McCrindle; Anne H Rowley; Jane W Newburger; Jane C Burns; Anne F Bolger; Michael Gewitz; Annette L Baker; Mary Anne Jackson; Masato Takahashi; Pinak B Shah; Tohru Kobayashi; Mei-Hwan Wu; Tsutomu T Saji; Elfriede Pahl Journal: Circulation Date: 2017-03-29 Impact factor: 29.690
Authors: Leora R Feldstein; Erica B Rose; Steven M Horwitz; Jennifer P Collins; Margaret M Newhams; Mary Beth F Son; Jane W Newburger; Lawrence C Kleinman; Sabrina M Heidemann; Amarilis A Martin; Aalok R Singh; Simon Li; Keiko M Tarquinio; Preeti Jaggi; Matthew E Oster; Sheemon P Zackai; Jennifer Gillen; Adam J Ratner; Rowan F Walsh; Julie C Fitzgerald; Michael A Keenaghan; Hussam Alharash; Sule Doymaz; Katharine N Clouser; John S Giuliano; Anjali Gupta; Robert M Parker; Aline B Maddux; Vinod Havalad; Stacy Ramsingh; Hulya Bukulmez; Tamara T Bradford; Lincoln S Smith; Mark W Tenforde; Christopher L Carroll; Becky J Riggs; Shira J Gertz; Ariel Daube; Amanda Lansell; Alvaro Coronado Munoz; Charlotte V Hobbs; Kimberly L Marohn; Natasha B Halasa; Manish M Patel; Adrienne G Randolph Journal: N Engl J Med Date: 2020-06-29 Impact factor: 91.245
Authors: Lara S Shekerdemian; Nabihah R Mahmood; Katie K Wolfe; Becky J Riggs; Catherine E Ross; Christine A McKiernan; Sabrina M Heidemann; Lawrence C Kleinman; Anita I Sen; Mark W Hall; Margaret A Priestley; John K McGuire; Konstantinos Boukas; Matthew P Sharron; Jeffrey P Burns Journal: JAMA Pediatr Date: 2020-09-01 Impact factor: 16.193
Authors: Patrick Davies; Claire Evans; Hari Krishnan Kanthimathinathan; Jon Lillie; Joseph Brierley; Gareth Waters; Mae Johnson; Benedict Griffiths; Pascale du Pré; Zoha Mohammad; Akash Deep; Stephen Playfor; Davinder Singh; David Inwald; Michelle Jardine; Oliver Ross; Nayan Shetty; Mark Worrall; Ruchi Sinha; Ashwani Koul; Elizabeth Whittaker; Harish Vyas; Barnaby R Scholefield; Padmanabhan Ramnarayan Journal: Lancet Child Adolesc Health Date: 2020-07-09
Authors: Rachel Harwood; Benjamin Allin; Christine E Jones; Elizabeth Whittaker; Padmanabhan Ramnarayan; Athimalaipet V Ramanan; Musa Kaleem; Robert Tulloh; Mark J Peters; Sarah Almond; Peter J Davis; Michael Levin; Andrew Tometzki; Saul N Faust; Marian Knight; Simon Kenny Journal: Lancet Child Adolesc Health Date: 2020-09-18